

1 **TITLE**

2 Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States

3

4 Fang Fang<sup>1</sup>, John David Clemens<sup>1,2,3</sup>, Zuo-Feng Zhang<sup>1,4,5</sup>, Timothy F. Brewer<sup>1,6</sup>

5 1. Department of Epidemiology, Fielding School of Public Health, University of California  
6 at Los Angeles (UCLA), Los Angeles, CA, USA

7 2. International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh

8 3. International Vaccination Institute (IVI), Seoul, the Republic of Korea

9 4. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA

10 5. Center for Human Nutrition, Department of Medicine, UCLA David Geffen School of  
11 Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA

12 6. Division of Infectious Diseases, UCLA David Geffen School of Medicine, Los Angeles,  
13 CA, USA

14 Co-Correspondent Authors:

15 Timothy F. Brewer, MD, MPH

16 Professor of Epidemiology and Medicine

17 Division of Infectious Diseases

18 UCLA David Geffen School of Medicine

19 10833 Le Conte Ave

20 CHS 52-215

21 Los Angeles, CA 90095-1688

22 [TBrewer@mednet.ucla.edu](mailto:TBrewer@mednet.ucla.edu)

23

24 Zuo-Feng Zhang, MD, PhD

25 Professor of Epidemiology and Medicine

26 UCLA Fielding Schools of Public Health and Medicine

27 650 Charles Young Drive, South

28 Los Angeles, CA 90095-1772

29 U.S.A.

30 [zfzhang@ucla.edu](mailto:zfzhang@ucla.edu)

31

32 **ABSTRACT**

33 **Background:** Despite safe and effective vaccines to prevent Severe Acute Respiratory  
34 Syndrome coronavirus 2 (SARS-CoV-2) infections and disease, a substantial minority of the US  
35 remains resistant to getting vaccinated. It is imperative to know if expanding vaccination rates  
36 could reduce community-wide Coronavirus 2019 (COVID-19) disease, not just among those  
37 vaccinated.

38 **Methods:** Negative binomial models were used to estimate associations between U.S. county-  
39 level vaccination rates and county-wide COVID-19 incidence and mortality between April 23<sup>rd</sup>  
40 and September 30<sup>th</sup>, 2021. A two-week lag and a four-week lag were introduced to assess  
41 vaccination rate impact on incidence and mortality, respectively. Stratified analyses were  
42 performed for county vaccination rates >40%, and before and after Delta became the dominant  
43 variant.

44 **Findings:** Among 3,070 counties, each percentage increase in population vaccination rates  
45 reduced county-wide COVID-19 incidence by 0.9% (relative risk (RR) 0.9910 (95% CI: 0.9869,  
46 0.9952)) and mortality by 1.9% (RR 0.9807 (95% CI: 0.9745, 0.9823)). Among counties with  
47 vaccination coverage >40%, each percentage increase in vaccination rates reduced COVID-19  
48 disease by 1.5%, RR 0.9850 (95% CI: 0.9793, 0.9952) and mortality by 2.7% (RR 0.9727 (95%  
49 CI: 0.9632, 0.9823)). These associations were not observed among counties with <40%  
50 vaccination rates. Increasing vaccination rates from 40% to 80% would have reduced COVID-19  
51 cases by 45.4% (RR 0.5458 (95% CI: 0.4335, 0.6873)) and deaths by 67.0% (RR 0.3305 (95%  
52 CI: 0.2230, 0.4898)). An estimated 5,989,952 COVID-19 cases could have been prevented and  
53 127,596 lives saved had US population vaccination rates increased from 40% to 80%.

54 **Interpretations:** Increasing U.S. SARS-CoV-2 vaccination rates results in population-wide  
55 reductions in COVID-19 incidence and mortality. Furthermore, increasing vaccination rates  
56 above 40% has protective effects among non-vaccinated persons. Given ongoing vaccine  
57 hesitancy in the U.S., increasing vaccination rates could better protect the entire community and  
58 potentially reach herd immunity.

59 **Funding:** National Cancer Institute

## 60 INTRODUCTION

61 Since being recognized in December, 2019, the Severe Acute Respiratory Syndrome coronavirus  
62 2 (SARS-CoV-2) pandemic has caused almost 250 million cases and five million deaths  
63 worldwide.<sup>1</sup> The United States has been particularly affected, with more than 43 million  
64 Coronavirus 2019 (COVID-19) cases and 697,000 deaths reported as of September 30<sup>th</sup>, 2021.<sup>2</sup>  
65 Though a number of non-pharmacologic prevention initiatives (NPIs) have been introduced to  
66 slow SARS-CoV-2 transmission<sup>3</sup>, vaccines are now recognized as among the most effective  
67 means for preventing COVID-19 cases and deaths.<sup>4</sup>

68  
69 Three vaccine preparations are authorized for use in the US. The BNT162b2 vaccine (Pfizer, Inc.  
70 and BioNTech), has full U.S. Food and Drug Administration (FDA) approval<sup>5</sup>, while mRNA-  
71 1273 (Moderna) and JNJ-78436735 (Janssen Pharmaceuticals) are available under an emergency  
72 use authorization. All three vaccines are effective in preventing SARS-CoV-2 infections and  
73 COVID-19 associated disease, hospitalizations, and deaths,<sup>6-8</sup> though vaccine effectiveness  
74 wanes over time and breakthrough infections occur.<sup>4,9</sup> Vaccine effectiveness also varies by  
75 SARS-CoV-2 variant, with higher rates of breakthrough infections or disease reported in  
76 vaccinated persons infected with Delta or Beta compared with other variants.<sup>8,10</sup> With the  
77 recognition of waning vaccine immunity and the rise of Delta as the predominant SARS-CoV-2  
78 variant in the U.S., the FDA has authorized the emergency use of a booster for COVID-19  
79 vaccines, including the use of a heterologous booster.<sup>11,12</sup>

80

81 Numerous studies have demonstrated that SARS-CoV-2 vaccines are effective in preventing  
82 COVID-19 infections and disease in individuals outside of clinical trials, including among health  
83 care workers, first responders, individuals attending ambulatory clinics, veterans, and in nursing  
84 homes.<sup>13-15</sup> Despite the proven safety and effectiveness of these vaccines, a substantial minority  
85 of the adult US population remains resistant to getting vaccinated.<sup>16</sup> To understand if the SARS-  
86 CoV-2 pandemic can be stopped, it is imperative to understand the impact of vaccination on  
87 community-wide SARS-CoV-2 cases and COVID-19 disease, not just among those vaccinated—  
88 a concept popularly referred to as “herd immunity”.<sup>17</sup> To investigate the impact of population  
89 percentages of SARS-CoV-2 vaccination on community-wide COVID-19 case and mortality  
90 rates, we undertook an ecological analysis of U.S. county vaccination rates on reported county  
91 COVID-19 cases and deaths, controlling for socioeconomic, demographic, comorbid conditions,  
92 rural/urban, air pollution, hospital capacity, and related factors, the introduction of NPIs and the  
93 presence of Delta variant.

94

## 95 **METHODS**

96 Negative binomial models were used to estimate associations between U.S. county-level  
97 vaccination rates and county-wide COVID-19 incidence and mortality between April 23<sup>rd</sup> and  
98 September 30<sup>th</sup>, 2021. The dates represent when Delta was first recognized in the U.S. to the end  
99 of the study period. To account for the rise of Delta as the dominant U.S. variant, additional  
100 analyses were done dividing the study period into before (April 23<sup>rd</sup> – July 2<sup>nd</sup>) and after (July  
101 3<sup>rd</sup> – September 30<sup>th</sup>) Delta was responsible for the majority of reported U.S. COVID-19 cases.

102

103 Both models were adjusted for the following potential confounders: annual average of ambient  
104 atmospheric particulate matter  $<2.5 \mu\text{m}$  in diameter ( $\text{PM}_{2.5}$ ) between 2000 and 2016, population  
105 density, poverty, education, proportions of White, proportions of male, proportion of population  
106 older than 65 years old, owner-occupied property, median house value, median household  
107 income, percentage of people under 65 years old without health insurance, prevalence of tobacco  
108 smoking, and obesity. All covariates were measured at the county level. State-level variables for  
109 NPIs policies (facemask mandates, stay home orders) also were included in both models. The  
110 mortality model additionally adjusted for the number of county hospital beds.

111  
112 County-level COVID-19 case and mortality data were obtained from the Johns Hopkins  
113 University, Center for Systems Science and Engineering Coronavirus Resource Center (CSSE).  
114 CSSE collects county-level confirmed numbers of cases and deaths of 3,342 counties across the  
115 U.S. from the U.S. Centers for Disease Control and Prevention (CDC) as well as state  
116 departments of health since January 21<sup>st</sup>, 2020.<sup>2</sup>

117  
118 County-level vaccine data were obtained from Covid Act Now. These data are derived from the  
119 U.S. Department of Health and Human Services, the CDC, the New York Times, and official  
120 state and county dashboards. Data on vaccinations initiated and vaccination regimens completed  
121 were available for all 50 states.<sup>18</sup> To allow for the development of protective immunity after  
122 vaccination, a two-week lag was introduced after people were completely vaccinated (a person  
123 vaccinated on June 18<sup>th</sup> was considered fully protected by July 2<sup>nd</sup>). A two-week lag also was  
124 used to account for time between exposure and development of COVID-19 disease. To assess the

125 impact of vaccination on COVID-19 mortality, a four-week lag was used (vaccinated by  
126 September 2<sup>nd</sup> to assess the impact on mortality on September 30<sup>th</sup>).

127

128 County-level annual average of PM<sub>2.5</sub> between the years 2000 and 2016, as well as county-level  
129 covariates, were available from a GitHub repository.<sup>19</sup> County-level socioeconomic and  
130 demographic variables for 2018 were available from the US Census/American Community  
131 Survey. 2020 data on the prevalence of adult tobacco smoking and adult obesity were accessible  
132 through the County Health Rankings & Roadmaps program.<sup>20</sup> The number of county hospital  
133 beds were obtained from an ArcGIS Hub dataset.<sup>21</sup> State averages were used to replace missing  
134 values for county-level prevalence for smoking, obesity, and numbers of hospital beds. U.S.  
135 Department of Agriculture 2013 rural and urban codes<sup>22</sup> were used to identify whether a county  
136 was located in metropolitan areas. State-wide non-pharmacologic prevention policies, including  
137 facemask use and stay home orders, were obtained from the Boston University School of Public  
138 Health.<sup>23</sup>

139

140 Counties with invalid Federal Information Processing Standards (n = 10), missing covariates (n =  
141 236), missing vaccination status on June 4<sup>th</sup> (n = 4), and negative change in incidence (n = 22) or  
142 in mortality (n = 61) possibly due to data entry error were excluded. As a result, data from 3,070  
143 counties in 49 states were available to investigate the association between population vaccination  
144 rates and county-wide COVID-19 incidence and 3,031 counties in 49 states to investigate the  
145 association between vaccination rates and COVID-19 mortality (Table 1).

146



147 As the average US county total population complete vaccination rate at the time of analysis was  
148 approximately 40%, further stratified analyses were performed investigating associations  
149 between counties where >40% of the total population was completely vaccinated with those with  
150 <40% complete population vaccination rates. The impact of 10% incremental increases in total  
151 population vaccine coverage was assessed in sensitivity analyses. To account for the correlation  
152 within each state, we applied the robust error estimation.<sup>24</sup> Relative risks (RR) and 95%  
153 confidence intervals (CI) are reported. Analyses were performed in SAS 9.4 (Cary, NC). To  
154 estimate the number of COVID-19 cases or deaths that could have been prevented during the  
155 study period by increasing county-wide vaccination rates, RRs were multiplied by the total at-  
156 risk US population. The at-risk population was estimated using the total 2021 U.S. population,  
157 subtracting the number of reported COVID-19 cases and deaths when estimating the population  
158 at risk for COVID-19 incidence and reported COVID-19 deaths only when estimating the  
159 population at risk for COVID-19 mortality.

160

## 161 **RESULTS**

162 Among the 3,070 counties across 49 states, the average county total population complete  
163 vaccination rate was 42.3% as of September 16<sup>th</sup>, 2021. Counties with >40% complete  
164 vaccination rates had more hospital beds, higher median house values, higher median household  
165 incomes, higher population density, and less uninsured population compared with counties with  
166 <40% vaccination rates. These counties also were more likely to be located in metropolitan areas  
167 and in states where a facemask policy was ever issued before September 30<sup>th</sup>, 2021 (Table 2).

168

169 Overall, each percentage increase in a county's total population vaccination rate between April  
170 23<sup>rd</sup> and September 30<sup>th</sup>, 2021 was associated with a 0.9% reduction in county-wide COVID-19

171 cases (relative risk (RR) 0.9910 (95% CI: 0.9869, 0.9952)) and a 1.9% reduction in county-wide  
172 COVID-19 mortality (RR 0.9807 (95% CI: 0.9745, 0.9823)). County population vaccination was  
173 associated with greater protection against COVID-19 infection, RR of 0.9895 (95% CI: 0.9851,  
174 0.9940), and mortality, RR 0.9742 (95% CI: 0.9670, 0.9804), when the analysis was limited to  
175 July 3<sup>rd</sup> to September 30<sup>th</sup>, corresponding to when Delta became the predominant SARS-CoV-2  
176 variant in the U.S. (Table 3).

177

178 Among the 1,686 counties in 49 states with complete vaccination coverage >40% as of  
179 September 16<sup>th</sup>, each percentage increase in county complete vaccination rates reduced the  
180 county population RR of COVID-19 disease by 1.5%, RR 0.9850 (95% CI: 0.9793, 0.9952).  
181 However, in counties with <40% complete vaccination rates, the association became null, RR  
182 1.0021 (95% CI: 0.9957, 1.0084). In the 1,442 counties in 49 states with vaccination rate >40%  
183 as of September 2<sup>nd</sup>, each percentage increase in the vaccination rate reduced county-wide  
184 COVID-19 mortality by 2.7% (RR 0.9727 (95% CI: 0.9632, 0.9823)). In contrast, increasing  
185 vaccination rates were not associated with reductions in county-wide COVID-19 mortality  
186 among counties with <40% population vaccination rates (RR 0.9938 (95% CI: 0.9849, 1.0027)).  
187 Similar results were observed before and after Delta became the most dominant U.S. variant, as  
188 well as when further stratifying by 10% incremental increases in vaccination rates (Table 3).

189

190 Compared to a county with 40% of its total population being completely vaccinated, increasing  
191 the population vaccination rate to 80% would have reduced COVID-19 cases by 45.4% (RR  
192 0.5458 (95% CI: 0.4335, 0.6873)) between April 23<sup>rd</sup> and September 30<sup>th</sup> and COVID-19 deaths  
193 by 67.0% (RR 0.3305 (95% CI: 0.2230, 0.4898)). Given the at-risk US population, an estimated

194 5,989,952 COVID-19 cases could have been prevented and 127,596 lives saved had US  
195 population vaccination rates increased from 40% to 80% (Table 4 and Table 5).

196

## 197 **DISCUSSION**

198 Data from 3,070 counties across 49 states demonstrates that each percentage increase in people  
199 being completely vaccinated was associated with a 0.9% decrease in population-wide COVID-19  
200 cases and a 1.9% reduction in COVID-19 mortality between April 23<sup>rd</sup> and September 30<sup>th</sup>, 2021  
201 after adjusting for potential confounders. Limiting the analysis to between July 3<sup>rd</sup> and  
202 September 30<sup>th</sup>, when Delta was the predominant US variant, gave similar results; each  
203 percentage increase in population vaccination rates was associated with a 1.1% decrease in  
204 county-wide COVID-19 cases and a 2.6% reduction in COVID-19 deaths. Among the counties  
205 with vaccination rate >40%, an additional percentage increase in vaccination rate was associated  
206 with a 1.5% reduction in population COVID-19 cases and 2.7% decrease in COVID-19  
207 mortality. In contrast, null associations were observed for counties with <40% coverage of  
208 complete vaccination rates. If a county increased its complete vaccination coverage from <40%  
209 to 80% during the study period, 45.4% infections and 67.0% deaths due to COVID-19 might  
210 have been prevented.

211

212 This study is among the first to demonstrate the impact of increasing SARS-CoV-2 vaccination  
213 rates on population-wide reductions in COVID-19 incidence and mortality. As the percentage  
214 reductions in population COVID-19 cases and deaths generally exceeded the percentage  
215 increases in population vaccination rates, these data suggest that increasing population  
216 vaccination rates has spillover protective effects among non-vaccinated persons. Moreover, these

217 spillover protective effects grow as population vaccination rates rise. Given ongoing vaccine  
218 hesitancy in the US, these results show how increasing vaccination rates could better protect the  
219 entire community and potentially reach herd immunity.

220  
221 We observed clear reductions in COVID-19 cases and deaths with rising population SARS-CoV-  
222 2 vaccination rates among counties with >40% vaccination coverage, but not among those with  
223 <40% population vaccination rates. This observation was consistent with the Israeli study  
224 showing declined COVID-19 incidence as vaccination rates increased.<sup>25</sup> Similar results were  
225 found in the stratified analyses of 10% incremental increases in vaccination rates. Though these  
226 data do not enable us to determine the population vaccine rate necessary to achieve herd  
227 immunity, the results showed that at least a 40% population vaccine coverage rate is needed to  
228 see a protective impact of vaccination among the entire population.

229  
230 The study was subject to several limitations. First, ecologic study designs are vulnerable to the  
231 ecologic fallacy. Therefore, caution is required when interpreting the study results, especially  
232 when extrapolating population findings to the individual level. In addition, we cannot rule out the  
233 possibility of residual confounding even after controlling for numerous county-level and state-  
234 level covariates. Using COVID-19 reported cases may underestimate of the number of actual  
235 infections due to under-testing of asymptomatic patients. However, alternative estimates for  
236 cumulative incidence, such as seroprevalence<sup>26</sup>, also have limitations including sampling bias,  
237 test sensitivity and specificity, and the progress of the pandemic.<sup>27</sup> Our analysis was not able to  
238 assess the impact of the three different vaccines currently available in the U.S., which likely had

239 different efficacies. Although a detailed distribution of different variants in the U.S. was not  
240 available, we examined the associations before and after the Delta variant became the  
241 predominant strain. Therefore, our results represent the associations between vaccine rates  
242 overall and COVID-19 incidence and mortality in the U.S. for vaccines as actually deployed and  
243 SARS-CoV-2 variants as they circulated during the period of our analysis.

244

245 The differential impact of rising population vaccination rates between before and after the spread  
246 of Delta variant might be due to the proportion of counties achieving >40% complete vaccination  
247 coverage. Before July 3<sup>rd</sup>, <30% of counties reached 40% population vaccination rates; almost  
248 half of counties had >40% of their total population vaccinated by September 30<sup>th</sup>, 2021. Finally,  
249 there was limited power to assess impact in counties with vaccination rates <20% or >70%. As a  
250 result, counties were combined into either < or >40%, the approximate U.S. county average, to  
251 obtain sufficient power and to account for the heterogeneity.

252

253 Nevertheless, this study is the first to estimate the association between complete vaccination  
254 rates and COVID-19 incidence and mortality in the U.S. general population using county-level  
255 data. This nation-wide study covers 3,070 counties in 49 states across the entire country,  
256 showing the population-based impact of increasing complete vaccination rates. The proportion of  
257 the Delta variant surpassed the proportion of the Alpha variant and accounted for >50% of  
258 infection in the U.S. as of June 26<sup>th</sup>, 2021.<sup>12</sup> Our results indicated that increasing complete  
259 vaccination rates were associated with reduced COVID-19 incidence and mortality overall and  
260 after July 3<sup>rd</sup>, demonstrating the vaccine impact within communities against SARS-CoV-2

261 variants in the U.S. including the Delta variant. The population-wide protective associations  
262 observed only among counties with >40% vaccination rates urge the uptake of vaccines in all  
263 counties. Though we showed estimated COVID-19 incidence and mortality reductions with  
264 complete vaccination rates increasing above 40%, these results should be interpreted with  
265 caution since there were limited data for counties with very high vaccination coverage rates.  
266 Future research should examine the barriers to vaccine uptake, especially among under-  
267 privileged populations, as well as estimate the vaccination coverage needed to reach the herd  
268 immunity.

269

## 270 **CONTRIBUTORS**

271 ZF Zhang conceptualized and supervised the project. ZF Zhang and F Fang developed the  
272 methods. F Fang obtained the data, conducted the analysis and wrote the original draft. JD  
273 Clemens, TF Brewer and ZF Zhang provided feedback on the analyses and edited the draft. All  
274 authors reviewed and revised the manuscript for critical content.

275

## 276 **DECLARATION OF INTERESTS**

277 F Fang and TF Brewer held stock in Pfizer. All other authors declare no competing interests.

278

## 279 **ACKNOWLEDGEMENTS**

280 We acknowledged all organizations and groups collecting and maintaining the publicly available  
281 data sources listed in Table 1 and utilized in this study. F Fang is supported by the NIH/NCI T32  
282 CA009142. The funding source did not involve in this study.

283

284 **Table 1. Summary of data sources**

Sources	Description
Johns Hopkins University Center for Systems Science and Engineering Coronavirus Resource Center (CSSE) <sup>2</sup>	Cumulative county-level confirmed cases and deaths up to September 30, 2021
Covid Act Now <sup>18</sup>	Cumulative county-level number of people completely vaccinated up to September 16, 2021
GitHub repository <sup>19</sup>	Annual average PM <sub>2.5</sub> concentration between 2000 and 2016
The US Census/American Community Survey	County-level socioeconomic and demographic variables in 2018
The County Health Rankings & Roadmaps program <sup>20</sup>	County-level behavioral variables in 2020
ArcGIS hub <sup>21</sup>	Numbers of hospital beds in each county
Economic Research Service <sup>22</sup>	Urban/rural code in 2013
Boston University of Public Health <sup>23</sup>	State-level policy of face masks mandates and stay home orders

285

286



287 **Table 2. Characteristics of counties (n = 3,070) in 49 states by vaccination rate as of 9/16**

	Total (n = 3,070 in 49 states)	Vaccination rate <sup>3</sup> on 9/16 ≤ 40% (n = 1,384 in 39 states)	Vaccination rate <sup>3</sup> on 9/16 > 40% (n = 1,686 in 49 states)
	Mean (SD)	Mean (SD)	Mean (SD)
Incidence of COVID-19 as of 9/30 (%) <sup>1</sup>	13.75 (3.84)	14.58 (3.94)	13.07 (3.63)
Incidence of COVID-19 as of 7/2 (%) <sup>1</sup>	10.25 (3.09)	10.50 (3.14)	10.04 (3.04)
Mortality of COVID-19 as of 9/30 (%) <sup>2</sup>	0.24 (0.13)	0.27 (0.13)	0.22 (0.12)
Mortality of COVID-19 as of 7/2 (%) <sup>2</sup>	0.21 (0.12)	0.22 (0.11)	0.19 (0.11)
Full vaccination rate as of 9/16 (%) <sup>3</sup>	42.27 (10.59)	33.26 (5.28)	49.66 (7.74)
Full vaccination rate as of 9/2 (%) <sup>3</sup>	40.60 (10.71)	31.56 (5.24)	48.01 (8.03)
Full vaccination rate as of 6/18 (%) <sup>3</sup>	34.75 (10.24)	26.73 (5.30)	41.32 (8.48)
Full vaccination rate as of 6/4 (%) <sup>3</sup>	32.95 (9.62)	25.55 (5.17)	39.03 (8.05)
Average ambient PM <sub>2.5</sub> (µg/m <sup>3</sup> ) <sup>4</sup>	8.41 (2.52)	8.30 (2.53)	8.51 (2.51)
Ever smokers (%)	17.45 (3.54)	18.35 (3.59)	16.71 (3.32)
Adult obesity (%)	32.88 (5.41)	33.89 (5.05)	32.05 (5.55)
Number of hospital beds	398.59 (1103.58)	175.30 (233.47)	581.89 (1448.76)
Population living in poverty (%)	15.63 (6.43)	16.97 (6.24)	14.53 (6.37)
Population density per square mile	267.33 (1817.39)	61.91 (171.05)	435.95 (2434.89)
Owner occupied properties (%)	71.60 (8.06)	72.61 (7.13)	70.77 (8.66)
Population 25 years old and older with less than high school education (%)	20.57 (6.09)	22.48 (5.94)	19.00 (5.75)
White Americans population (%)	83.51 (16.25)	84.43 (15.62)	82.75 (16.73)
African Americans population (%)	9.13 (14.57)	9.05 (13.95)	9.20 (15.07)
Hispanic population (%)	9.21 (13.76)	8.47 (12.08)	9.82 (14.97)
Median house value (×\$1,000)	145.80 (87.18)	114.56 (40.55)	171.45 (105.05)
Median household income (×\$1,000)	51.40 (13.56)	46.94 (9.94)	55.07 (14.97)
Population over 65 years old (%)	20.28 (4.81)	20.25 (4.48)	20.31 (5.08)
Male (%)	50.06 (2.14)	50.35 (2.44)	49.82 (1.82)
Uninsured population (%)	8.88 (3.97)	10.40 (3.97)	7.64 (3.52)
Metropolitan, n (%)			
Yes	1151 (37.49)	649 (31.43)	486 (55.16)
No	1919 (62.51)	1416 (68.57)	395 (44.84)
State stay-home order before 9/30, n (%)			
Ever issued	2709 (88.24)	1218 (88.01)	1491 (88.43)
Never issued	361 (11.76)	166 (11.99)	195 (11.57)
State facemask policy before 9/30, n (%)			
Ever issued	2297 (74.82)	867 (62.64)	1430 (84.82)
Never issued	773 (25.18)	517 (37.36)	256 (15.18)

<sup>1</sup>COVID-19 cases out of total population in each county

<sup>2</sup>COVID-19 deaths out of total population in each county

<sup>3</sup>Number of people fully vaccinated out of total population in each county

<sup>4</sup>Annual average of PM<sub>2.5</sub> between 2000 and 2016

288 **Table 3. Adjusted RRs of COVID-19 incidence and mortality associated with additional people**  
 289 **fully vaccinated per 100 population by vaccination rates**

	RR		
	(95% CI with naïve standard error estimation)		
	(95% CI with robust standard error estimation)		
Incidence <sup>1</sup> (n = 3,070 in 49 states)	4/23/2021 – 7/2/2021 <sup>3</sup>	7/3/2021 – 9/30/2021 <sup>4</sup>	4/23/2021 – 9/30/2021 <sup>4</sup>
	0.9960	0.9895	0.9910
Overall	(0.9935, 0.9986) (0.9877, 1.0044)	(0.9875, 0.9915) (0.9851, 0.9940)	(0.9892, 0.9929) (0.9869, 0.9952)
Above 40%	0.9857 (0.9795, 0.9920) (0.9768, 0.9947)	0.9836 (0.9805, 0.9867) (0.9771, 0.9901)	0.9850 (0.9821, 0.9878) (0.9793, 0.9907)
70% and above	NA	NA	0.9933 (0.9525, 1.0360) (0.9506, 1.0380)
60% - 69%	NA	NA	0.9917 (0.9729, 1.0107) (0.9706, 1.0131)
50% - 59%	NA	NA	0.9798 (0.9679, 0.9918) (0.9682, 0.9915)
40% - 49%	NA	NA	0.9907 (0.9825, 0.999) (0.9825, 0.999)
Below 40%	0.9968 (0.9924, 1.0012) (0.9847, 1.0091)	1.0015 (0.9963, 1.0068) (0.9951, 1.0080)	1.0021 (0.9970, 1.0071) (0.9957, 1.0084)
30% - 39%	NA	NA	0.9976 (0.9879, 1.0075) (0.9887, 1.0067)
20% - 29%	NA	NA	1.0268 (1.0063, 1.0477) (1.0095, 1.0444)
Below 20%	NA	NA	1.0199 (0.9580, 1.0858) (0.9622, 1.0809)
Mortality <sup>2</sup> (n = 3,031 in 49 states)	4/23/2021 – 7/2/2021 <sup>5</sup>	7/3/2021 – 9/30/2021 <sup>6</sup>	4/23/2021 – 9/30/2021 <sup>6</sup>
	0.9971	0.9742	0.9807
Overall	(0.9933, 1.0009) (0.9878, 1.0065)	(0.9706, 0.9779) (0.9670, 0.9815)	(0.9779, 0.9835) (0.9745, 0.9869)
Above 40%	0.9773 (0.9651, 0.9897) (0.9613, 0.9936)	0.9685 (0.9616, 0.9754) (0.9567, 0.9804)	0.9727 (0.9679, 0.9775) (0.9632, 0.9823)
70% and above	NA	NA	1.0682 (0.9594, 1.1894)

			(0.9882, 1.1547)
			1.0013
60% - 69%	NA	NA	(0.9676, 1.0362)
			(0.9675, 1.0363)
			0.9618
50% - 59%	NA	NA	(0.9434, 0.9806)
			(0.9440, 0.9800)
			0.9775
40% - 49%	NA	NA	(0.9634, 0.9917)
			(0.9612, 0.9940)
	1.0050	0.9899	0.9938
Below 40%	(0.9995, 1.0105)	(0.9820, 0.9978)	(0.9873, 1.0003)
	(0.9896, 1.0206)	(0.9792, 1.0007)	(0.9849, 1.0027)
			0.9849
30% - 39%	NA	NA	(0.9731, 0.9968)
			(0.9726, 0.9973)
			1.0189
20% - 29%	NA	NA	(0.9923, 1.0462)
			(0.9953, 1.0431)
			1.0947
Below 20%	NA	NA	(0.9843, 1.2174)
			(1.0388, 1.1536)

<sup>1</sup>Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never) and facemask mandate before 9/30 (ever/never)

<sup>2</sup>Model 2 adjusts for all covariates in model 1 + number of hospital beds

<sup>3</sup>Percentage of fully vaccinated population as of 6/18/2021, 877 counties in 47 states with complete vaccination rate above 40% and 2,193 counties in 42 states with complete vaccination rate below 40%

<sup>4</sup>Percentage of fully vaccinated population as of 9/16/2021, 1,686 counties in 49 states with complete vaccination rate above 40% (1,032 counties in 43 states with vaccination rate between 40% and 49%, 471 counties in 46 states with vaccination rate between 50% and 59%, 149 counties in 32 states with vaccination rate between 60% and 69%, and 34 counties in 20 states with vaccination rate of 70% and above) and 1,384 counties in 39 states with complete vaccination rate below 40% (36 counties in 14 states with vaccination rate below 20%, 260 counties in 32 states with vaccination rate between 20% and 29%, and 1,088 counties in 39 states with vaccination rate between 30% and 39%)

<sup>5</sup>Percentage of fully vaccinated population as of 6/4/2021, 684 counties in 47 states with complete vaccination rate above 40% and 2,347 counties in 44 states with complete vaccination rate below 40%

<sup>6</sup>Percentage of fully vaccinated population as of 9/2/2021, 1,442 counties in 49 states with complete vaccination rate above 40% (906 counties in 43 states with vaccination rate between 40% and 49%, 395 counties in 45 states with vaccination rate between 50% and 59%, 131 counties in 31 states with vaccination rate between 60% and 69%, and 29 counties in 19 states with vaccination rate of 70% and above) and 1,589 counties in 44 states with complete vaccination rate below 40% (43 counties in 15 states with vaccination rate of below 20%, 394 counties in 33 states with vaccination rate between 20% and 29%, and 1,172 counties in 40 states with vaccination rate between 30% and 39%)

291 **Table 4. Estimated adjusted RRs, risk reductions of COVID-19 incidence and cases could have**  
 292 **been prevented associated with complete vaccination rates between April 23 and September 30,**  
 293 **2021**

	RR <sup>1</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Cases per 100,000 population <sup>2</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Cases could have been prevented <sup>3</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)
Counties with 40% complete vaccination rate	1.0000	4568.96	0
Counties with 50% complete vaccination rate (each 10% increase)	0.8595 (0.8352, 0.8846) (0.8114, 0.9105)	3927.02 (3816.00, 4041.70) (3707.25, 4160.04)	1,852,902 (1,521,886, 2,173,369) (1,180,319, 2,487,241)
Counties with 60% complete vaccination rate (each 20% increase)	0.7388 (0.6975, 0.7826) (0.6584, 0.8290)	3375.55 (3186.85, 3575.67) (3008.20, 3787.67)	3,444,684 (2,867,053, 3,989,345) (2,255,134, 4,504,992)
Counties with 70% complete vaccination rate (each 30% increase)	0.6350 (0.5825, 0.6923) (0.5343, 0.7548)	2901.29 (2661.42, 3163.09) (2441.20, 3448.65)	4,813,590 (4,057,922, 5,505,955) (3,233,677, 6,141,613)
Counties with 80% complete vaccination rate (each 40% increase)	0.5458 (0.4865, 0.6124) (0.4335, 0.6873)	2493.74 (2222.80, 2798.03) (1980.64, 3140.25)	5,989,952 (5,111,636, 6,771,995) (4,123,862, 7,470,955)
Counties with 90% complete vaccination rate (each 50% increase)	0.4692 (0.4063, 0.5418) (0.3518, 0.6258)	2143.76 (1856.37, 2475.46) (1607.36, 2859.26)	7,000,146 (6,042,703, 7,829,666) (4,934,918, 8,548,408)

<sup>1</sup>Percentage of fully vaccinated population as of 9/16/2021; Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never) and facemask mandate before 9/30 (ever/never)

<sup>2</sup>The average incidence among counties with less than 40% complete vaccination rates

<sup>3</sup>The at-risk population was estimated using the total 2021 U.S. population, subtracting the number of reported COVID-19 cases and the number of reported COVID-19 deaths

294

295 **Table 5. Estimated adjusted RRs, risk reductions of COVID-19 mortality and deaths could have**  
 296 **been prevented associated with complete vaccination rates between April 23 and September 30,**  
 297 **2021**

	RR <sup>1</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Deaths per 100,000 population <sup>2</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Deaths could have been prevented <sup>3</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)
Counties with 40% complete vaccination rate	1.0000	57.39	0
Counties with 50% complete vaccination rate (each 10% increase)	0.7582 (0.7219, 0.7963) (0.6872, 0.8366)	43.51 (41.43, 45.70) (39.44, 48.01)	46,083 (38,822, 53,001) (31,141, 59,615)
Counties with 60% complete vaccination rate (each 20% increase)	0.5749 (0.5211, 0.6342) (0.4722, 0.6999)	32.99 (29.90, 36.40) (27.10, 40.17)	81,017 (69,716, 91,271) (57,194, 100,590)
Counties with 70% complete vaccination rate (each 30% increase)	0.4359 (0.3762, 0.5050) (0.3245, 0.5855)	25.02 (21.59, 28.98) (18.62, 33.60)	107,509 (94,339, 118,886) (78,997, 128,740)
Counties with 80% complete vaccination rate (each 40% increase)	0.3305 (0.2716, 0.4022) (0.2230, 0.4898)	18.97 (15.59, 23.08) (12.80, 28.11)	127,596 (113,931, 138,822) (97,236, 148,084)
Counties with 90% complete vaccination rate (each 50% increase)	0.2506 (0.1961, 0.3203) (0.1532, 0.4098)	14.38 (11.25, 18.38) (8.79, 23.52)	142,824 (129,540, 153,211) (112,483, 161,387)

<sup>1</sup>Percentage of fully vaccinated population as of 9/2/2021; Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never), facemask mandate before 9/30 (ever/never) and number of hospital beds

<sup>2</sup>The average mortality among counties with less than 40% complete vaccination rates

<sup>3</sup>The at-risk population was estimated using the total 2021 U.S. population, subtracting the number of reported COVID-19 deaths

298

299

## 300 REFERENCE

- 301 1. World Health Organization. COVID-19 Weekly Epidemiological Update. Geneva: World  
302 Health Organization, 2021.
- 303 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in  
304 real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
- 305 3. Fang F, Mu L, Zhu Y, Rao J, Heymann J, Zhang Z-F. Long-Term Exposure to PM2.5,  
306 Facemask Mandates, Stay Home Orders and COVID-19 Incidence in the United States.  
307 *International Journal of Environmental Research and Public Health* 2021; **18**(12): 6274.
- 308 4. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19  
309 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med* 2021; **385**(4): 320-9.
- 310 5. U.S. Food and Drug Administration. FDA Approves First COVID-19 Vaccine. August  
311 23, 2021 2021. [https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine)  
312 [19-vaccine](https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine) (accessed August 26, 2021 2021).
- 313 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
314 Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
- 315 7. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months  
316 after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine*  
317 2021.
- 318 8. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose  
319 Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**(23): 2187-201.
- 320 9. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in  
321 Health Care Workers in California. *N Engl J Med* 2021.

- 322 10. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and  
323 Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021.  
324 *MMWR Morb Mortal Wkly Rep* 2021; **70**(37): 1306-11.
- 325 11. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Takes  
326 Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. Silver Spring, MD;  
327 2021.
- 328 12. Centers for Disease Control and Prevention. Variant Proportions. 2021.  
329 <https://covid.cdc.gov/covid-data-tracker/#variant-proportions> (accessed July 3, 2021 2021).
- 330 13. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in  
331 Ambulatory and Inpatient Care Settings. *N Engl J Med* 2021; **385**(15): 1355-71.
- 332 14. Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 Vaccine Effectiveness in  
333 a High-Risk National Population in a Real-World Setting. *Ann Intern Med* 2021.
- 334 15. Cabezas C, Coma E, Mora-Fernandez N, et al. Associations of BNT162b2 vaccination  
335 with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes  
336 and healthcare workers in Catalonia: prospective cohort study. *Bmj* 2021; **374**: n1868.
- 337 16. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes  
338 Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann Intern Med* 2020;  
339 **173**(12): 964-73.
- 340 17. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity  
341 to SARS-CoV-2 infection by mass vaccination. *Lancet* 2020; **396**(10263): 1614-6.
- 342 18. Covid Act Now. Covid Act Now API. 2021 ed; 2021.



- 343 19. Wu X, Nethery RC, Sabath MB, Braun D, Dominici F. Air pollution and COVID-19  
344 mortality in the United States: Strengths and limitations of an ecological regression analysis.  
345 *Science Advances* 2020; **6**(45): eabd4049.
- 346 20. The County Health Rankings & Roadmaps program. Health Behaviors. 2020.  
347 [https://www.countyhealthrankings.org/explore-health-rankings/measures-data-sources/county-](https://www.countyhealthrankings.org/explore-health-rankings/measures-data-sources/county-health-rankings-model/health-factors/health-behaviors)  
348 [health-rankings-model/health-factors/health-behaviors](https://www.countyhealthrankings.org/explore-health-rankings/measures-data-sources/county-health-rankings-model/health-factors/health-behaviors).
- 349 21. GeoPlatform ArcGIS Online. Hospitals. 2020.  
350 <https://hub.arcgis.com/datasets/geoplatform::hospitals/about> (accessed July 3, 2021 2021).
- 351 22. Economic Research Service. Rural-Urban Continuum Codes. 2020.  
352 <https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/2021>).
- 353 23. Raifman J, Nocka K, Jones D, et al. COVID-19 US state policy database. 2020.
- 354 24. Gotway CA, Stroup WW. A Generalized Linear Model Approach to Spatial Data  
355 Analysis and Prediction. *Journal of Agricultural, Biological, and Environmental Statistics* 1997;  
356 **2**(2): 157-78.
- 357 25. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA  
358 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and  
359 deaths following a nationwide vaccination campaign in Israel: an observational study using  
360 national surveillance data. *The Lancet* 2021; **397**(10287): 1819-29.
- 361 26. Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-  
362 2 infections with cumulative and imputed COVID-19 cases: Systematic review. *PLOS ONE*  
363 2021; **16**(4): e0248946.
- 364 27. Accorsi EK, Qiu X, Rumpler E, et al. How to detect and reduce potential sources of  
365 biases in studies of SARS-CoV-2 and COVID-19. *Eur J Epidemiol* 2021; **36**(2): 179-96.



